Streetbeat News

BMEA

Biomea Fusion, Inc.

Industry

Biotechnology

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Open

2.73

Mkt cap

92M

Volume

650K

High

2.80

P/E Ratio

-0.63

52-wk high

17.89

Low

2.48

Div yield

N/A

52-wk low

2.35

Citigroup analyst Yigal Nochomovitz has reiterated a Buy rating on Biomea Fusion (NASDAQ:BMEA) and maintained a $90 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 5:17 pm

Biomea Fusion Inc (NASDAQ:BMEA) reported results from a Phase 2 study and preclinical ex-vivo human islet experiments for BMF-219, a treatment for type 2 diabetes. The study showed improved HbA1c levels in participants, with varying degrees of efficacy based on dosage and food intake. BMF-219 also demonstrated potential benefits in beta cell mass and function. Despite these findings, BMEA shares dropped 17.90% to $12.35.

Portfolio Pulse from Vandana Singh

December 08, 2023 | 4:48 pm

Biomea Fusion's stock price has declined following the announcement of long-term follow-up data from its Phase II study of BMF-219 in adults with type 2 diabetes, which was presented at WCIRDC.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 3:49 pm

Verint Systems Inc. (VRNT) reported strong third-quarter earnings, surpassing market estimates and saw its shares rise by 14%. Other stocks also moved higher, including Semtech Corporation (SMTC) after reporting earnings and guidance, and Alphabet Inc. (GOOGL) following the launch of Gemini AI. Notably, Cerevel Therapeutics Holdings, Inc. (CERE) surged after an acquisition announcement by AbbVie Inc. (ABBV).

Portfolio Pulse from Avi Kapoor

December 07, 2023 | 3:17 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. EyePoint Pharmaceuticals (EYPT) saw a substantial increase of 172.8%, while Alterity Therapeutics (ATHE) and Altimmune (ALT) also had notable gains. Conversely, NexImmune (NEXI), BioAtla (BCAB), and Vivos Therapeutics (VVOS) were among the stocks that declined.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 5:31 pm

Science Applications International Corporation (SAIC) reported Q3 results with a slight revenue decline but beat consensus estimates and raised FY24 guidance, causing its shares to surge by 6.9%. Other stocks also moved higher, including Hawaiian Holdings (HA) after an acquisition announcement by Alaska Air Group (ALK), and several companies like Wallbox (WBX), CleanSpark (CLSK), and Carvana (CVNA) due to various positive developments. Uber (UBER) rose after news it would join the S&P 500 index.

Portfolio Pulse from Lisa Levin

December 04, 2023 | 3:33 pm

Patterson Companies, Inc. (PDCO) shares fell by 14% after reporting Q2 earnings of $0.50 per share, missing estimates of $0.58 per share, and lowering FY24 adjusted EPS guidance below expectations. The company's sales were $1.65 billion, below the expected $1.70 billion. Other stocks moved in the mid-day session with various companies experiencing significant gains or losses due to various factors such as FDA clearances, earnings reports, acquisition announcements, and public offerings.

Portfolio Pulse from Lisa Levin

November 29, 2023 | 7:02 pm

Health care stocks experienced significant movement in Wednesday's intraday session. Vivos Therapeutics (VVOS) saw a massive increase of 312.8%, while BioVie (BIVI) faced a sharp decline of 61.9%. Other notable gainers include China Pharma Holding (CPHI), Altamira Therapeutics (CYTO), Envoy Medical (COCH), Biomea Fusion (BMEA), and vTv Therapeutics (VTVT). On the losing side, BiomX (PHGE), Eagle Pharmaceuticals (EGRX), Journey Medical (DERM), Biodexa Pharmaceuticals (BDRX), and Patterson Cos (PDCO) saw significant drops, with PDCO specifically reacting to its Q2 earnings report.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 5:31 pm

Workday, Inc. (NASDAQ:WDAY) shares increased by approximately 9% in pre-market trading following the company's release of third-quarter earnings that exceeded expectations. Workday reported earnings of $1.56 per share, surpassing the estimated $1.41 per share, and revenue of $1.87 billion, which was higher than the forecasted $1.848 billion. The company expects fourth-quarter subscription revenue of $6.598 billion and adjusted operating margins of 23.8%. Piper Sandler maintained an Overweight rating on Workday and increased the price target from $275 to $300. The article also lists other stocks that moved in pre-market trading, with some experiencing significant gains and others facing declines.

Portfolio Pulse from Lisa Levin

November 29, 2023 | 1:11 pm

In Wednesday's pre-market session, several healthcare stocks showed significant movement. Vivos Therapeutics (VVOS) saw a substantial increase of 132.6%, while Avenue Therapeutics (ATXI) and Redhill Biopharma (RDHL) also experienced notable gains. Conversely, Eagle Pharmaceuticals (EGRX) and Heart Test Laboratories (HSCS) were among the stocks that declined. Patterson Cos (PDCO) reported Q2 earnings, which may have influenced its stock decrease.

Portfolio Pulse from Benzinga Insights

November 29, 2023 | 1:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.